Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...
Setser dismissed Apple Inc.'s (AAPL) claim that it will invest $500 billion in the U.S. over the next four years. "Apple is taking credit for making orders for TSMC's future chip production in the U.S ...
For greater potential upside, consider earlier-stage smid-cap biotech names. Small- and midcap biotech stocks are riskier, but have been hardest hit in the sector's decline. "Smid-cap biotech looks ...
Nio (NYSE:NIO) shares fell sharply Thursday after the electric vehicle (EV) maker announced a proposed offering of approximately 118.8 million shares, representing 5.4% of its total outstanding shares ...
Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't ...
Citi analyst Geoff Meacham keeps a Neutral rating on Pfizer (PFE) with a $27 price target after the Wall Street Journal reported that U.S.
StockStory.org on MSN13h
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals StocksAs the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals ...
Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results